X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Victoza-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2024
Details:
Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Victoza-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2024
Details:
Under the agreement, Biocon will undertake the responsibility of obtaining regulatory approval, manufacturing and supply of Saxenda (liraglutide), used in the treatment of chronic weight management, and Medix will be responsible for its commercialization in the Mexican market.
Lead Product(s): Liraglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Saxenda-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2024
Details:
The financing is intended to support the company's lead product, 4P-004 (liraglutide), which is currently undergoing evaluation in early-stage clinical trials with patients for treating Knee Osteoarthritis.
Lead Product(s): Liraglutide
Therapeutic Area: Musculoskeletal Product Name: 4P-004
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 29, 2024
Details:
Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Lirafit (liraglutide biosimilar) is a glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs). It is now approved in India for the treatment of adult patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Lirafit
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
4P004, a GLP1 analog, is a novel first-in-class drug candidate addressing a high unmet medical need. The purpose is to potentially change the natural course of osteoarthritis to prevent long-term disability.
Lead Product(s): Liraglutide
Therapeutic Area: Musculoskeletal Product Name: 4P004
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Saxenda-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Juno Pharmaceuticals Pty Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 06, 2023
Details:
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
